**Name of journal: *World Journal of Virology***

**ESPS Manuscript NO: 14870**

**Columns: MINIREVIEW**

**Early initiation of antiretroviral treatment: Challenges in the Middle East and North Africa**

Sardashti S *et al.* Feasibility of early initiation of ART in MENA

Sara Sardashti, Mehrnoosh Samaei, Mona Mohammadi Firouzeh, Seyed Ali Mirshahvalad, Fatemeh Golsoorat Pahlaviani, SeyedAhmad SeyedAlinaghi

**Sara Sardashti, Mehrnoosh Samaei, Mona Mohammadi Firouzeh, Seyed Ali Mirshahvalad, Fatemeh Golsoorat Pahlaviani, SeyedAhmad SeyedAlinaghi,** Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran 14-19-733141, Iran

**Author contributions:** Sardashti S and SeyedAlinaghi SA made substantial contributions to conception and design of the study, review of the literature, interpretation of findings, and drafting the article; Samaei M, Firouzeh MM, Mirshahvalad SA, Pahlaviani FG contributed to integration of findings through literature review and drafting of the manuscript; Sardashti S made critical revisions; SeyedAlinaghi SA made the final approval.

**Conflict-of-interest:** The authors certify that they have no affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials discussed in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: SeyedAhmad SeyedAlinaghi, MD, MPhil,** Iranian Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Imam Khomeini Hospital, Keshavarz Boulevard, Tehran 14-19-733141, Iran. s\_a\_alinaghi@yahoo.com

**Telephone:** +98-21-66947984

**Fax:** +98-21-66947984

**Received:** October 28, 2014

**Peer-review started:** October 30, 2014

**First decision:** November 27, 2014

**Revised:** January 30, 2015

**Accepted:** February 9, 2015

**Article in press:**

**Published online:**

**Abstract**

New World Health Organization (WHO) guidelines recommend the initiation of antiretroviral treatment (ART) for asymptomatic patients with CD4 counts of ≤ 500 cells/mm3. Substantial reduction of HIV transmission is addressed as a major public health outcome of this new approach. Middle East and North Africa (MENA), known as the area of controversies in terms of availability of comprehensive data, has shown concentrated epidemics among most of it’s at risk population groups. Serious challenges impede the applicability of new guidelines in the MENA Region. Insufficient resources restrict ART coverage to less than 14%, while only one fourth of the countries had reportable data on patients’ CD4 counts at the time of diagnosis. Clinical guidelines need to be significantly modified to reach practical utility, and surveillance systems have not yet been developed in many countries of MENA. Based on available evidence in several countries people who inject drugs and men who have sex with men are increasingly vulnerable to HIV and viral hepatitis, while their sexual partners - either female sex workers or women in monogamous relationships with high-risk men - are potential bridging populations that are not appropriately addressed by regional programs. Research to monitor the response to ART among the mentioned groups are seriously lacking, while drug resistant HIV strains and limited information on adherence patterns to treatment regimens require urgent recognition by health policymakers. Commitment to defined goals in the fight against HIV, development of innovative methods to improve registration and reporting systems, monitoring and evaluation of current programs followed by cost-effective modifications are proposed as effective steps to be acknowledged by National AIDS Programs of the countries of MENA Region.

**Key words:** Antiretroviral agents; HIV; CD4 counts; Co-infections; Regional health planning

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The main purpose of the present review was to investigate the feasibility of new World Health Organization guidelines on earlier initiation of antiretroviral treatment in resource-limited settings, specifically in the Middle East and North Africa region.

Sardashti S, Samaei M, Firouzeh MM, Mirshahvalad SA, Pahlaviani FG, SeyedAlinaghi SA. Early initiation of antiretroviral treatment: Challenges in the Middle East and North Africa. *World J Virol* 2015; In press

**INTRODUCTION**

In 2013, recommendations regarding the early initiation of antiretroviral treatment (ART) were published by World Health Organization (WHO) in consolidated HIV treatment and prevention guidelines. Initiation of ART among asymptomatic adults and adolescents with CD4+ T-cell counts of ≤ 500 cells/mm3, regardless of clinical stage is strongly recommended in this guideline[1].

Previous guidelines (2010) suggested that treatment be initiated for patients with CD4 counts of ≤ 350 cells/mm3[2]. Several recent studies provide evidence of substantially reduced risks of HIV transmission among serodiscordant couples, if ART is initiated when CD4 counts range from 350 to 550 cells/mm3[3]. Hence new recommendations have a greater focus on public health issues concerning HIV transmission.

Although the new guidelines delineate the earlier initiation of ART as “highly cost-effective”, adaptation of these recommendations is a significant challenge for many countries including those in the Middle East and North Africa (MENA). Evidence from most of the 23 countries of MENA has indicated a significant increase in HIV incidence and AIDS-related deaths in the recent decade; nonetheless, antiretroviral coverage was reported to be less than 14% by the end of 2011[1-4].

From a social perspective, the cultural context that prohibits HIV related high-risk behaviors encourages ubiquitous stigma that affects access to available services in the MENA countries[4-7]. Availability and allocation of resources, on the other hand, has been threatened by ongoing conflicts and high rates of migration[8-12]. From a public health perspective, in many countries of the MENA lack of integrated data on HIV incidence rates and disease progression among known patients requires to be increased[8]. In addition, scarcity of gender-sensitive programs and lack of systematic approach in development of national guidelines hinder enactment of new treatment strategies in MENA[4,5,13,14]. HIV epidemic is characterized by rising incidence and prevalence rates among key at-risk populations, specifically among people who inject drugs (PWID)[12].

Hence the co-infections that are diagnosed more commonly among these population groups require particular attention in the implementation of the ART guidelines[15,16]. Additionally, in many countries of the region where cost-effective tests for viral load and CD4+ T-cell counts are not available and retention in care is not well understood, monitoring of response to ART and disease progression inherits location-specific challenges in adapting ART guidelines[17].

Previous studies that have investigated the quality of clinical practice guidelines in the region indicate that serious gaps; including outdated or inconsistent clinical contents, weak methodology in tailoring recommendations, and insufficient applicability[13].

The development of HIV treatment protocols that are coordinated with international standards requires better knowledge of the epidemiological and clinical characteristics of patient populations in the region[13,18]. Hence, we highlight the available evidence-based information that may benefit research scientists, clinicians, and health authorities of the region in their attempts at scaling up of HIV/AIDS programs including ART coverage.

**RESEARCH**

To conduct the present study, we searched PubMed, Embase, and local databases for all relevant articles published from the MENA region. Also, published results of incomplete cohorts and other related studies that investigated early initiation of antiretroviral regimens or initiation among at-risk populations, including articles not available before June 2013 were accessed through PubMed and Google search engines; online library of the International AIDS Society and Research Gate were also screened for possible research works. Publications with findings that are important in the context of HIV/AIDS responses among low and middle income countries in other parts of the world were also used for the review.

Major search key words and phrases included, but were not limited to, the following: “early antiretroviral initiation + 2013-14”, “ART and HIV-HCV”, “ART and HIV-HBV”, “ART and HIV-TB”, “ART cost-effectiveness”, “HIV retention in care”, “HIV antiretroviral adherence”, “HIV and drug resistance”, “HIV-HCV PWID”, “HIV/AIDS MENA region”, “PWID in MENA”, “MSM, FSWs in MENA region”; all the keywords were specifically searched for in publications from countries of the MENA region.

**ART INITIATION BASED ON CD4+ T-CELL COUNTS**

Available antiretroviral drugs are prescribed to delay immunologic failure and control HIV-related diseases rather than to eradicate the virus[19]. CD4+ T-cell counts are the most utilized, and probably available, immunologic marker for clinicians to decide for initiation of ART[20]. This test also serves as a predictor of rates of AIDS and non-AIDS related causes of death[21,22]. However, many resource- limited settings still depend on the WHO clinical staging system for decision-making[17].

According to a recent short report, only six of the countries in MENA had reportable data on patients’ initial CD4 counts at the time of diagnosis in 2011, and eight countries had provided similar data in 2009. In most countries over 50% of the patients were ART eligible meaning they had CD4 counts of ≤ 350 cells/mm3 at the time of diagnosis[5,18]. Development or improvement of standard and organized surveillance systems in settings where CD4 measurements are available seems a priority in the region[18,23]. In resource-limited countries, WHO clinical staging if carefully adapted in practice should provide as an accurate substitute to accelerate response in these areas[17].

**IMPLEMENTING ART UPTAKE AMONG AT-RISK POPULATIONS**

Concentrated HIV epidemics have been reported among at least one of the high-risk population groups (PWIDs, female/male sex workers, MSM) in all countries of the region[11]. However, at least in ten countries out of 23, HIV surveillance is not available among most at risk groups and sample size estimations of most at risk groups using primary data acquisition has been established only in Pakistan[18]. Overall, HIV prevalence, and concurrent high-risk behaviors of injecting drug users have been widely investigated within MENA countries[24,25]. MSM and FSWs are the two other major groups; in recent years their HIV risk behaviors have been better understood in several countries of the region[11]. Evidence also suggests that the disproportionate prevalence of HIV among men is related to unknown sexual behaviors and drug use as overlapping high-risk activities[5]. Nevertheless, no studies are available concerning response to ART or patterns of treatment adherence among HIV infected patients who are affiliated with these high-risk groups; nor is there sufficient evidence from the other countries regarding improved outcomes due to the early initiation of ART among PWIDs and other high risk groups[20].

***PWIDs***

From 13 MENA countries that have published evidence-based data on PWIDs, epidemics are reported as being concentrated in Pakistan, Iran, Afghanistan, Egypt, Morocco and Libya[26]. While increasing trends are reported in Pakistan, Iran and Egypt, Libya has recently been facing the highest HIV prevalence (87%) among PWIDs in the region[27].

The burden of disease related to blood-borne infections among PWIDs remains high and raises global concerns[4,11,28]. The MENA region is no exception, and expansion of harm reduction programs is essential for effectively fighting HIV. Hepatitis C (HCV) and hepatitis B (HBV) are also not targeted appropriately despite higher transmission rates compared to HIV[26].

Management of HBV or HCV co-infections in HIV patients has been a matter of controversy for years[20]. Although ART regimens have shown benefits in several studies, despite moderate levels of liver toxicity among non-injectors[23,29], serious hepatic complications impede initiation of ART among PWIDs[24]. Study of a large cohort of more than 60 thousand people living with HIV/AIDS in Europe and North America has led to the proposal that liver-related causes of death, including hepatitis and liver failure, are the most common causes of mortality among PWIDs during and after the first year of ART initiation[15]. For example, Nevirapine-based regimens may lead to elevated CD4 levels in HIV-HBV co-infected patients[29], however, the very complicated immunopathology of viral hepatitis co-infections in these patients requires evidence-based decisions that are suitable for the epidemic in the MENA Region[24]. We underscore the HIV and hepatitis co-infection prevalence among general and high-risk populations in various MENA countries in Table 1.

***Bridging populations***

New guidelines also suggest that ART should be initiated among HIV patients who are in serodiscordant relationships, to reduce risk of transmission[1]. This recommendation is based on recent findings that indicate substantial decrease (89%) in virus transmission from infected patients to their uninfected partners, who were prescribed ART with CD4 counts of 350 to 550 cells/mm3 of blood[3]. A recent study from Iran provides valuable data on potential concentrated epidemics among the non-injecting sexual partners of PWIDs[7,30]; this study provides insights into the possibility of overlapping transmission between high-risk groups such as PWIDs and FSWs; considering the disproportionately high male-to-female prevalence and the lack of confirmatory surveys in the region, we cannot rule out the possibility of current or future hidden sub-epidemics among FSWs and MSM in certain countries of the region[18,30,31]. The existing gap between identified and estimated numbers of people infected with HIV may potentially feed the increasing vertical transmission of the virus in the near future[4,5,32].

Women in monogamous relationships with PWIDs or MSM, are perceived to have low rates of high-risk activities, but are at high risk of transmitting HIV, and probably also HBV and HCV to their newborns[26,30]. On the contrary these women do not have consistent access to HIV counseling and lack the willingness to test for HIV[4,33]. Hence, HIV awareness should be developed in parallel with HIV testing facilities to successfully implement HIV clinical guidelines in MENA region.

FSWs that also comprise a proportion of sexual partners of both PWIDs and men with same-sex behaviors are also a potential bridging population in transmitting HIV to the general population in MENA[11,30,34]. Notably rates of syphilis (weighted prevalence: 7.2%) in Iran[35], and of viral hepatitis reported among non-injecting FSWs in Afghanistan is relatively high[36].

**HIV AND TB IN MENA REGION**

Latest WHO estimates of the burden of disease caused by tuberculosis (TB) in the Eastern Mediterranean Region indicate a stable trend in TB mortality, prevalence, and incidence; these estimates introduce the region as a medium-burden area. Since 2010, New incidence of TB among HIV-infected patients in the region has remained steady [11 (10-12) thousand in 2012], however, no improvements are evident in case detection rates (CDRs) during this same period. In addition, lack of detection and surveillance systems suggests that these estimates may not fully capture actual incidence[37].

On the other hand, the number of reported patients with multi-drug resistant TB (MDR-TB) has tripled from 2007 to 2010 globally. Estimates show that 56% percent of these MDR-TB patients have been successfully treated in the Eastern Mediterranean Region, and despite better outcomes compared to other regions, this number is much lower than WHO’s defined goal of 75% for 2015[37]. Country-specific studies highlight the urgent need for addressing MDR-TB, specifically among patients who are re-treated with anti-TB drugs[38-40]. The situation is becoming especially critical in Saudi Arabia due to high influence of travelers and migrating laborers from TB endemic areas, and also in Somalia which reports the highest prevalence of MDR-TB in the region[41,42]. Similar situations cannot be precluded in other countries, where sufficient measures have not been taken into account.

New guideline recommends initiation of ART among all patients with active TB regardless of CD4 counts or clinical stage[1]. Comparison of migrant and non-migrant patients by the Antiretroviral Therapy Cohort Collaboration (ART-CC) revealed different AIDS-defining events in the two groups, with migrants from MENA displaying significantly higher rates of TB in the first year after initiation of ART[15]. Immune response to tuberculosis is blunted following ART initiation, and this suppression persists for years due to decreased alveolar macrophage activity and specific cellular responses[43]. Hence, patients that receive ART remain susceptible to TB, a challenge that requires further attention in TB endemic countries of MENA.

Simultaneous treatment of HIV and TB, as recommended by WHO, remains controversial because of patients who develop immune reconstitution syndrome (IRIS) after ART initiation, and show higher mortality rates. The reason why IRIS affects certain patients is not thoroughly understood, but may be linked to monocyte-derived responses[44]. Our expanding knowledge about human leukocyte antigens (HLA) associations observed among non-seroconverting partners of HIV patients should uncover a role for genetic factors in the future[45]. Context-specific decisions on the timing for initiation of ART among TB-infected patients are highly dependent on future findings of large cohorts among different high-risk groups from various ethnic backgrounds. Meanwhile, a scaling up of HIV testing and counseling and of efforts at detecting cases with MDR-TB should be considered a priority[36,46].

**ADHERENCE AND DRUG RESISTANCE**

Our knowledge about adherence to ART in MENA is limited to a few studies[47,48], which show that the role of stigma and discrimination, specifically among female patients, poses a major barrier to adherence[47]. A cross-sectional study conducted in Iran shows adherence rates of 65.5% (self-report) and 60.4% (pill count) during a three month follow-up; however, the short term follow-up and the limited number of patients evaluated in a single center setting limit our ability to generalize these findings. Results of this study indicate that living with family members, shifting to new ART regimens, and the stage of the disease are major correlates of higher adherence rates[48].

Although most evidence on the antiretroviral resistance profiles of ART-naïve and ART-treated patients is limited to a few studies[47-50], the critically high rates of resistance to antiretroviral regimens requires immediate attention in the countries of the region, with the goal of increasing availability of viral load tests and modification of ART regimens, based on genotype sequencing[51]. Policymakers should consider the cost-effectiveness of early ART initiation compared to scaling up of educational programs that target ART adherence, or to reaching out for the new and cheaper means of viral load measurement[52].

Studies conducted in resource poor settings emphasize that documentation of ART adherence through patient self-reports derived from administration of standard questionnaires, is not costly and helps to improve clinical outcomes (CD4 and viral load). Healthcare managers can also monitor ART distribution, availability of services, and counseling practices by utilizing metrics from these screenings[53]. Documentation about adherence is helpful in decreasing transmitted drug resistance, which in-turn may require inevitable high expenditure in the future in these countries.

**CONCLUSION**

Serious challenges need to be tackled before adapting new clinical guidelines in current healthcare settings in MENA counties. The general response of MENA countries to HIV epidemics although effective has not been proportionate to the increasing needs. Insufficient human and financial resources, presence of punitive laws and social stigma are barriers for implementation of prevention, treatment or care programs in this region. Additionally, the lack of consistent documentation, registration and reporting systems that is required for monitoring and evaluating the present situation of HIV impedes appropriate response.

We recommend the following as major areas requiring action by health authorities in MENA countries for successful adaptation of ART guidelines: (1) To manage registration of HIV prevalence and incidence, and to design innovative data registry systems where necessary; (2) To investigate and monitor the genetic sequence of the most common HIV strains, and drug resistance profiles of infected patients (*e.g.*, among different high-risk groups); (3) To conduct cohort studies to investigate clinical outcomes among large groups of patients to empower health policymakers and clinicians with relevant data; (4) To develop standard adherence measurement tools to promote adherence and to document findings required for proper resource allocation; (5) To design disease databases for prevalent HIV co-infections to help in potential revisions required in national guidelines based on local patient needs; and (6) To recognize the concomitant role of social stigma and access to illicit drugs (opiates or stimulants) in the future pattern of HIV epidemic in the region

Figure 1 summarizes the major areas that we suggest they need to be targeted by healthcare systems for development of new HIV treatment guidelines. We also suggest original research and implementation projects can be of prominent help in MENA. Based on computational models early initiation of ART could be of high impact in reducing immunologic failure[54]. In MENA region such innovative models could be of assistance among the networks of infected people to make size estimations and map distribution where the majority also has high-risk activities[32]. A practical approach could be to strengthen case detection systems through finding vulnerable people in each patient’s network to reduce the time to diagnosis in newly identified patients. This will reduce the probability of transmitting drug-resistant strains which could be a major concern in coming years. Recent clinical trials are also suggesting new treatment protocols; as an example alternating regimens that provide patients with intermittent combinations of antiretroviral agents are supposed to reduce the probability of multi-drug resistance[55]. These new protocols may be of prominent significance in the future of HIV epidemic in MENA region; however, their feasibility is yet to be established in settings with limited access to ART.

**REFERENCES**

1 **World Health Organization (WHO).** The uses of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach at June 2013. Available from: URL: http: //apps.who.int/iris/bitstream/10665/85321/1/9789241505727\_eng.pdf

2 **World Health Organization (WHO).** Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach at 2010. Available from: URL: http: //whqlibdoc.who.int/publications/2010/9789241599764\_eng.pdf

3 **Cohen MS**, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; **365**: 493-505 [PMID: 21767103 DOI: 10.1056/NEJMoa1105243]

4 **The United Nation Joint Program on HIV/AIDS (UNAIDS).** Regional report for the Middle East and North Africa at 2013. Available from: URL: http: //www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS\_Global\_Report\_2013\_en.pdf

5 **Bozicevic I**, Riedner G, Haghdoost A. HIV case reporting in the countries of North Africa and the Middle East. *J Int AIDS Soc* 2014; **17**: 18962 [PMID: 24815415 DOI: 10.7448/IAS.17.1.18962]

6 **Chahil-Graf R**, Madani N. Women, culture and the HIV epidemic in MENA. *J Int AIDS Soc* 2014; **17**: 19074 [PMID: 24629846 DOI: 10.7448/IAS.17.1.19074]

7 **Karamouzian M**, Akbari M, Haghdoost AA, Setayesh H, Zolala F. "I Am Dead to Them": HIV-related Stigma Experienced by People Living With HIV in Kerman, Iran. *J Assoc Nurses AIDS Care* 2014; **26**: 46-56 [PMID: 24856436 DOI: 10.1016/j.jana.2014.04.005]

8 **Abu-Raddad LJ**, Ghanem KG, Feizzadeh A, Setayesh H, Calleja JM, Riedner G. HIV and other sexually transmitted infection research in the Middle East and North Africa: promising progress? *Sex Transm Infect* 2013; **89** Suppl 3: iii1-iii4 [PMID: 24191291 DOI: 10.1136/sextrans-2013-051373]

9 **Ávila C**, Loncar D, Amico P, De Lay P. Determinants of government HIV/AIDS financing: a 10-year trend analysis from 125 low- and middle-income countries. *BMC Public Health* 2013; **13**: 673 [PMID: 23870494 DOI: 10.1186/1471-2458-13-673]

10 **Khajehkazemi R**, Sadeghirad B, Karamouzian M, Fallah MS, Mehrolhassani MH, Dehnavieh R, Haghdoost A. The projection of burden of disease in Islamic Republic of Iran to 2025. *PLoS One* 2013; **8**: e76881 [PMID: 24146941 DOI: 10.1371/journal.pone.0076881]

11 **Abu-Raddad LJ**, Hilmi N, Mumtaz G, Benkirane M, Akala FA, Riedner G, Tawil O, Wilson D. Epidemiology of HIV infection in the Middle East and North Africa. *AIDS* 2010; **24** Suppl 2: S5-23 [PMID: 20610949 DOI: 10.1097/01.aids.0000386729.56683.33]

12 **Mumtaz GR**, Riedner G, Abu-Raddad LJ. The emerging face of the HIV epidemic in the Middle East and North Africa. *Curr Opin HIV AIDS* 2014; **9**: 183-191 [PMID: 24445372 DOI: 10.1097/COH.0000000000000038]

13 **De Weggheleire A,** Bortolotti V, Zolfo M, Crowley S, Colebunders R, Riedner G, et al. Challenges in developing national HIV guidelines: experience from the eastern Mediterranean. Bulletin of the World Health Organization, 2011; **89**: 442-450. Available from: URL: http: //www.who.int/bulletin/volumes/89/6/10-083790/en/

14 **Alkaiyat A**, Weiss MG. HIV in the Middle East and North Africa: priority, culture, and control. *Int J Public Health* 2013; **58**: 927-937 [PMID: 23824483 DOI: 10.1007/s00038-013-0485-y]

15 **Collaboration ATC.** Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS (London, England), 2013; **27:** 1321. Available from: URL: http: //www.ncbi.nlm.nih.gov/pmc/articles/PMC3992322/

16 [**Antiretroviral Therapy Cohort Collaboration (ART-CC)**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Antiretroviral%20Therapy%20Cohort%20Collaboration%20(ART-CC)%5BCorporate%20Author%5D)**.** Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. *Clin Infect Dis* 2013; **56**: 1800-1809 [PMID: 23457077 DOI: 10.1093/cid/cit111]

17 **Munthali C**, Taegtmeyer M, Garner PG, Lalloo DG, Squire SB, Corbett EL, Ford N, MacPherson P. Diagnostic accuracy of the WHO clinical staging system for defining eligibility for ART in sub-Saharan Africa: a systematic review and meta-analysis. *J Int AIDS Soc* 2014; **17**: 18932 [PMID: 24929097 DOI: 10.7448/IAS.17.1.18932]

18 **Bozicevic I**, Riedner G, Calleja JM. HIV surveillance in MENA: recent developments and results. *Sex Transm Infect* 2013; **89** Suppl 3: iii11-iii16 [PMID: 23434789 DOI: 10.1136/sextrans-2012-050849]

19 **Chun TW**, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. *J Clin Invest* 2005; **115**: 3250-3255 [PMID: 16276421 DOI: 10.1172/JCI26197]

20 **Pandhi D**, Ailawadi P. Initiation of antiretroviral therapy. *Indian J Sex Transm Dis* 2014; **35**: 1-11 [PMID: 24958979 DOI: 10.4103/0253-7184.132399]

21 **Ingle SM**, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. *Clin Infect Dis* 2014; **59**: 287-297 [PMID: 24771333 DOI: 10.1093/cid/ciu261]

22 **Mellors JW**, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 1997; **126**: 946-954 [PMID: 9182471 DOI: 10.7326/0003-4819-126-12-199706150-00003]

23 **Holtedahl K**, Salpou D, Braaten T, Berved Z. Optimal starting point for antiretroviral HIV treatment in a town in Cameroon: a randomised controlled study. *BMC Public Health* 2014; **14**: 828 [PMID: 25108448 DOI: 10.1186/1471-2458-14-828]

24 **Nelson PK**, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571-583 [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0]

25 **Anglaret X**, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. *Antivir Ther* 2013; **18**: 45-55 [PMID: 22809695 DOI: 10.3851/IMP2231]

26 **Mumtaz GR**, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, Semini I, Tawil O, Akala FA, Wilson D, Abu-Raddad LJ. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. *PLoS Med* 2014; **11**: e1001663 [PMID: 24937136 DOI: 10.1371/journal.pmed.1001663]

27 **Mirzoyan L**, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, Turki AA, Saffialden R, Valadez JJ. New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. *J Acquir Immune Defic Syndr* 2013; **62**: 577-583 [PMID: 23337363 DOI: 10.1097/QAI.0b013e318284714a]

28 **The World Bank.** The Global HIV Epidemics among People Who Inject Drugs at 2013. Available from: URL: http: //www.worldbank.org/content/dam/Worldbank/document/GlobalHIVEpidemicsAmongPeopleWhoInjectDrugs.pdf

29 **Andreotti M**, Pirillo MF, Liotta G, Jere H, Maulidi M, Sagno JB, Luhanga R, Amici R, Mancini MG, Gennaro E, Marazzi MC, Vella S, Giuliano M, Palombi L, Mancinelli S. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. *BMC Infect Dis* 2014; **14**: 180 [PMID: 24708626 DOI: 10.1186/1471-2334-14-180]

30 **Alipour A**, Haghdoost AA, Sajadi L, Zolala F. HIV prevalence and related risk behaviours among female partners of male injecting drugs users in Iran: results of a bio-behavioural survey, 2010. *Sex Transm Infect* 2013; **89** Suppl 3: iii41-iii44 [PMID: 24064986 DOI: 10.1136/sextrans-2013-051201]

31 **Alkaiyat A**, Schaetti C, Liswi M, Weiss MG. Condom use and HIV testing among men who have sex with men in Jordan. *J Int AIDS Soc* 2014; **17**: 18573 [PMID: 24695243 DOI: 10.7448/IAS.17.1.18573]

32 **Saba HF**, Kouyoumjian SP, Mumtaz GR, Abu-Raddad LJ. Characterising the progress in HIV/AIDS research in the Middle East and North Africa. *Sex Transm Infect* 2013; **89** Suppl 3: iii5-iii9 [PMID: 23596206

 DOI: 10.1136/sextrans-2012-050888]

33 **Majid T**, Farhad Y, Sorour A, Soheila A, Farnaz F, Hojjat Z, Leili CT. Preventing Mother-to-Child Transmission of HIV/AIDS: Do Iranian Pregnant Mothers Know about it? *J Reprod Infertil* 2010; **11**: 53-57 [PMID: 23926481]

34 **Ahmadi K**, Rezazade M, Nafarie M, Moazen B, Yarmohmmadi Vasel M, Assari S. Unprotected Sex with Injecting Drug Users among Iranian Female Sex Workers: Unhide HIV Risk Study. *AIDS Res Treat* 2012; **2012**: 651070 [PMID: 22506107 DOI: 10.1155/2012/651070]

35 **Navadeh S**, Mirzazadeh A, Mousavi L, Haghdoost A, Fahimfar N, Sedaghat A. HIV, HSV2 and Syphilis Prevalence in Female Sex Workers in Kerman, South-East Iran; Using Respondent-Driven Sampling. *Iran J Public Health* 2012; **41**: 60-65 [PMID: 23641392]

36 **Todd CS**, Nasir A, Stanekzai MR, Bautista CT, Botros BA, Scott PT, Strathdee SA, Tjaden J. HIV, hepatitis B, and hepatitis C prevalence and associated risk behaviors among female sex workers in three Afghan cities. *AIDS* 2010; **24** Suppl 2: S69-S75 [PMID: 20610952 DOI: 10.1097/01.aids.0000386736.25296.8d]

37 **World Health Organization (WHO).** Global tuberculosis report at 2014. Available from: URL: http: //www.who.int/tb/publications/global\_report/en/

38 **Ghenghesh KS**, Rahouma A, Tawil K, Zorgani A, Franka E. Antimicrobial resistance in Libya: 1970-2011. *Libyan J Med* 2013; **8**: 1-8 [PMID: 23537612 DOI: 10.3402/ljm.v8i0.20567]

39 **Sindani I**, Fitzpatrick C, Falzon D, Suleiman B, Arube P, Adam I, Baghdadi S, Bassili A, Zignol M. Multidrug-resistant tuberculosis, Somalia, 2010-2011. *Emerg Infect Dis* 2013; **19**: 478-480 [PMID: 23621911 DOI: 10.3201/eid1903.121287]

40 **Velayati AA**, Farnia P, Mozafari M, Sheikholeslami MF, Karahrudi MA, Tabarsi P, Hoffner S. High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. *Am J Trop Med Hyg* 2014; **90**: 99-105 [PMID: 24189362 DOI: 10.4269/ajtmh.13-0057]

41 **Jamjoom GA**, Azhar EI, Madani TA, Hindawi SI, Bakhsh HA, Damanhouri GA. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia. *Saudi Med J* 2010; **31**: 987-992 [PMID: 20844809]

42 **Abouzeid MS**, Al RF, Memish ZA. Mortality among tuberculosis patients in Saudi Arabia (2001-2010). *Ann Saudi Med* 2013; **33**: 247-252 [PMID: 23793426 DOI: 10.5144/0256-4947.2013.247]

43 **Jambo KC**, Banda DH, Afran L, Kankwatira AM, Malamba RD, Allain TJ, Gordon SB, Heyderman RS, Russell DG, Mwandumba HC. Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria. *Am J Respir Crit Care Med* 2014; **190**: 938-947 [PMID: 25225948 DOI: 10.1164/rccm.201405-0864OC]

44 **Andrade BB**, Singh A, Narendran G, Schechter ME, Nayak K, Subramanian S, Anbalagan S, Jensen SM, Porter BO, Antonelli LR, Wilkinson KA, Wilkinson RJ, Meintjes G, van der Plas H, Follmann D, Barber DL, Swaminathan S, Sher A, Sereti I. Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. *PLoS Pathog* 2014; **10**: e1004433 [PMID: 25275318 DOI: 10.1371/journal.ppat.1004433]

45 **Silva ML,** Melo VH, Aleixo AW, Aleixo LF, Pascoal-Xavier MA, Silva RO, Ferreira LA, Domingos WC, Greco DB. Social and immunological differences among uninfected Brazilians exposed or unexposed to human immunodeficiency virus-infected partners. *Mem Inst Oswaldo Cruz* 2014; **109**: 775-781 [PMID: 25230129]

46 **Saleeb PG**, Buchwald UK. [Update on the epidemiology, diagnosis and therapy of tuberculosis in HIV-infected patients]. *Pneumologie* 2014; **68**: 666-675 [PMID: 25290921 DOI: 10.1055/s-0034-1377514]

47 **Badahdah AM**, Pedersen DE. "I want to stand on my own legs": A qualitative study of antiretroviral therapy adherence among HIV-positive women in Egypt. *AIDS Care* 2011; **23**: 700-704 [PMID: 21476148 DOI: 10.1080/09540121.2010.534431]

48 **Khalili H**, Rohani R, Seyedalinaghi S, Hajiabdolbaghi M, Dashti-Khavidaki S, Talasaz AH. Adherence to antiretroviral therapy among Iranian HIV/AIDS patients. *Curr Clin Pharmacol* 2012; **7**: 111-115 [PMID: 22432842]

49 **Feelemyer J,** Des Jarlais D, Arasteh K, Uusküla A. Adherence to Antiretroviral Medications Among Persons Who Inject Drugs in Transitional, Low and Middle Income Countries: An International Systematic Review. *AIDS Behav* 2014 [PMID: 25331268]

50 **Mohammadpour A**, Yekta ZP, Nikbakht Nasrabadi AR. HIV-infected patients' adherence to highly active antiretroviral therapy: a phenomenological study. *Nurs Health Sci* 2010; **12**: 464-469 [PMID: 21210925 DOI: 10.1111/j.1442-2018.2010.00560.x]

51 **Jahanbakhsh F**, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, Aghasadeghi MR, Mostafavi E, Mohraz M, Jabbari H, Kamali K, Keyvani H, Azadmanesh K, Sugiura W. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011. *PLoS One* 2013; **8**: e61864 [PMID: 23626742 DOI: 10.1371/journal.pone.0061864]

52 **Ekici H**, Rao SD, Sönnerborg A, Ramprasad VL, Gupta R, Neogi U. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. *J Antimicrob Chemother* 2014; **69**: 3349-3355 [PMID: 25085657 DOI: 10.1093/jac/dku278]

53 **Chalker JC**, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, Waako P, Ross-Degnan D. Measuring adherence to antiretroviral treatment in resource-poor settings: the feasibility of collecting routine data for key indicators. *BMC Health Serv Res* 2010; **10**: 43 [PMID: 20170479 DOI: 10.1186/1472-6963-10-43]

54 **Haering M**, Hördt A, Meyer-Hermann M, Hernandez-Vargas EA. Computational study to determine when to initiate and alternate therapy in HIV infection. *Biomed Res Int* 2014; **2014**: 472869 [PMID: 24900966 DOI: 10.1155/2014/472869]

55 **Martinez-Picado J**, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. *Ann Intern Med* 2003; **139**: 81-89 [PMID: 12859157 DOI: 10.7326/0003-4819-139-2-200307150-00007]

56 **Ruiseñor-Escudero H**, Wirtz AL, Berry M, Mfochive-Njindan I, Paikan F, Yousufi HA, Yadav RS, Burnham G, Vu A. Risky behavior and correlates of HIV and Hepatitis C Virus infection among people who inject drugs in three cities in Afghanistan. *Drug Alcohol Depend* 2014; **143**: 127-133 [PMID: 25131717 DOI: 10.1016/j.drugalcdep.2014.07.022]

57 **Abdulla AM,** Al Qamish RJ. Hepatitis C virus infection: a single center experience. Bahrain Medical Bulletin, 2008; **30:** 1-10. Available from: URL: http: //www.bahrainmedicalbulletin.com/march\_2008/Hepatitis\_C.pdf

58 **Abdel Messih IY**, Ismail MA, Saad AA, Azer MR. The degree of safety of family replacement donors versus voluntary non-remunerated donors in an Egyptian population: a comparative study. *Blood Transfus* 2014; **12**: 159-165 [PMID: 23245714 DOI: 10.2450/2012.0115-12]

59 **AL-Janabi AAHS,** AL-Masoudy AA. Serosurvey of HIV, HCV and HBV in Clinical Laboratory Workers of Karbala (Iraq) Health Care Units. *GJMS* 2009; **4:** 108-111. Available from: URL: http: //www.idosi.org/gjms/gjms4(2)/11.pdf

60 **SeyedAlinaghi S**, Jam S, Mehrkhani F, Fattahi F, Sabzvari D, Kourorian Z, Jabbari H, Mohraz M. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. *Acta Med Iran* 2011; **49**: 252-257 [PMID: 21713737]

61 **Rahimi-Movaghar A**, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. *Int J Infect Dis* 2010; **14**: e28-e33 [PMID: 19464218 DOI: 10.1016/j.ijid]

62 **AL-Gani FA.** Prevalence of HBV, HCV and HIV-1, 2 infections among blood donors in Prince Rashed Ben Al-Hassan Hospital in North Region of Jordan. *Int* *J Biol Med Res* 2011; **2**: 912-916

63 **Mahfoud Z**, Kassak K, Kreidieh K, Shamra S, Ramia S. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon. *J Infect Dev Ctries* 2010; **4**: 144-149 [PMID: 20351454 DOI: 10.3855/jidc.517]

64 **Rebbani K**, Ouladlahsen A, Bensghir A, Akil A, Lamdini H, Issouf H, Brahim I, Kitab B, Fakhir FZ, Wakrim L, Marhoum El Filali K, Himmich H, Ezzikouri S, Benjelloun S. Co-infections with hepatitis B and C viruses in human immunodeficiency virus-infected patients in Morocco. *Clin Microbiol Infect* 2013; **19**: E454-E457 [PMID: 23731409 DOI: 10.1111/1469-0691]

65 **Nafees M,** Qasim A, Jafferi Gh, Anwar MS, Muazzam M. HIV infection, HIV/HCV and HIV/HBV co-infections among jail inmates of Lahore. *Pak J Med Sci* 2011; **27:** 837-841

66 **Alzahrani AJ**, Dela Cruz DM, Obeid OE, Bukhari HA, Al-Qahtani AA, Al-Ahdal MN. Molecular detection of hepatitis B, hepatitis C, and torque teno viruses in drug users in Saudi Arabia. *J Med Virol* 2009; **81**: 1343-1347 [PMID: 19551834 DOI: 10.1002/jmv.21487]

67 **Fageeh W**, Iyer A, Almalki N, Alturkistani W, Yaghmoor S, et al. Prevalence and awareness of sexually transmitted infections among inmates of a drug rehabilitation center in Saudi Arabia: a cross-sectional study. *Epidemiology* 2014; **4:** 154 [DOI: 10.4172/2161-1165.1000154]

68 **Kilani B**, Ammari L, Marrakchi C, Letaief A, Chakroun M, Ben Jemaa M, Ben Aïssa HT, Kanoun F, Ben Chaabène T. Seroepidemiology of HCV-HIV coinfection in Tunisia. *Tunis Med* 2007; **85**: 121-123 [PMID: 17665657]

**P-Reviewer:** Arriagada GL, Farzin R, Qiu HJ **S-Editor:** Ji FF **L-Editor: E-Editor**

**Table 1 Evidence-based prevalence rates of HIV, hepatitis B and C co-infections in 13 countries of the Middle East and North Africa region**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Country - city names****(yr)** | **Target population****(*n*)1** | **HIV prevalence****(%)** | **Methodology** | **HCV2****(Isolated or co-infection prevalence %)** | **HBV2****(Isolated or co-infection prevalence %)** |
| **Afghanistan - three cities (2009)[36,56]** | FSWs (*n* = 520)PWIDs | 0.19%7.1% (1% to 18.4%) | Cross-sectionalCross-sectional | Isolated: 1.92%Isolated: 40.3%Co-infection: 94.9% | Isolated: 6.54% (range: 3% to 17.5%)Isolated: 7.1% |
| **Bahrain - Bahrain (2002-2006)[57]** | HCV infected patients (*n* = 183) | 0.5% | Retrospective cohort | HCV-HBV co-infection:3.3% | - |
| **Egypt - Cairo (2010)[58]** | Blood donors-family members (*n* = 15017) | 0.01% | Cross-sectional | Isolated: 4.3% | Isolated: 1.7% |
| **Iraq - Karbala****(2009)[59]** | Healthcare workers(*n* = 124) | 0 | Cross-sectional | 0 | 0 |
| **Iran - Tehran****(2007)[60]** | PWIDs(*n* = 899) | 10.7% | Cross-sectional | Isolated: 34.5%Co-infection: 80.6% | Isolated: 50.7%Co-infection: 7.8% |
| **Jordan (2009)[61]** | Blood donors(*n* = 8190) | 0 | Cross-sectional | Isolated: 0.9% | Isolated: 1.4% |
| **Lebanon - Beirut (2008)[62]** | Inmates(*n* = 580) | 0.17% | Cross-sectional | Isolated: 3.43% | Isolated: 2.4% |
| **Libya - Tripoli****(2013)[27]** | PWIDs (*n* = 328)  | 87% | Respondent-driven sampling | Co-infection: 83% | Co-infection: 4% |
| **Morocco - Casablanca (2006-2010)[63]** | HIV infected patients of a referral clinic(*n* = 504) | All patients were infected. | Cohort | 5.4% | Co-infection: 5.2% |
| **Pakistan - Lahore****(2011)[64]** | Inmates (*n* = 4915)  | 2.01% | Cross-sectional | Co-infection: 73.74%  | 0.01% (HBV/HCV Co-infections: 77.78%) |
| **Saudi Arabia****(2009)[65]****(2012)[66]** | PWIDs(*n* = 344)Rehab center inmates-drug users(*n* = 115) | Not checked4% | Cross-sectionalCross-sectional | Isolated: 38% (HBV-HCV: 3.5%)- | Isolated: 12% (HBV DNA)Isolated: 4% |
| **Tunisia (2007)[67]** | HIV infected patients(*n* = 362) | Not applicable | Cross-sectional | Co-infection: 39.7%(For PWIDs: 87.4%) | - |
| **Yemen - Hodeidah** **(2010)[68]** | Blood donors (*n* = 1483) | 0.14% | Cross-sectional | Isolated: 0.79% | Isolated: 2.35% |

1Sample size; 2Lab evaluations: Anti-HIV antibody (enzymatic immunoassay or western blot; Anti-HCV antibody; HBs antigen (enzymatic immunoassay).

**Implementation of ART guidelines in MENA: major factors**

**Figure 1 Major challenge for development of HIV treatment guidelines in Middle East and North Africa.** MENA: Middle East and North Africa; ART: Antiretroviral treatment.